Raman Singh Sells 29,494 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 29,494 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $60.13, for a total value of $1,773,474.22. Following the sale, the director owned 38,755 shares of the company’s stock, valued at $2,330,338.15. This trade represents a 43.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Liquidia Stock Up 3.2%

Shares of NASDAQ:LQDA opened at $62.03 on Thursday. The company has a market capitalization of $5.52 billion, a PE ratio of 443.10 and a beta of 0.41. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The business has a fifty day moving average price of $43.52 and a two-hundred day moving average price of $38.05. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $63.46.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia announced that CEO Roger Jeffs and CFO/COO Michael Kaseta will present a business update at the 2026 Jefferies Global Healthcare Conference on June 3, which can help keep investor attention on the company and its growth story. Article Title
• Positive Sentiment: Analysts continue to view Liquidia favorably, with the stock carrying a “Moderate Buy” consensus and several firms recently lifting price targets or upgrading ratings, which supports the rally. Article Title
• Neutral Sentiment: Insider filings showed CEO Roger Jeffs and Director Raman Singh sold shares in recent days, including a 25,000-share sale by the CEO under a pre-arranged 10b5-1 plan; while these trades can raise caution, the sales were disclosed and do not necessarily signal a change in operating outlook. Article Title

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LQDA. HC Wainwright upped their price objective on Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Oppenheimer upped their price objective on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research note on Thursday, March 12th. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research note on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research note on Monday, May 11th. Finally, Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. bought a new position in shares of Liquidia during the 4th quarter worth $25,000. NewEdge Advisors LLC bought a new position in shares of Liquidia during the 2nd quarter worth $25,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Liquidia during the 3rd quarter worth $30,000. FNY Investment Advisers LLC bought a new position in shares of Liquidia during the 3rd quarter worth $34,000. Finally, Covestor Ltd grew its stake in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the period. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).